A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase

NCT00435604 | Completed Phase 1

• 1 other identifier: HZ2-07-01
• Study Type: interventional
• Target: 15
• Locations: 0 countries
• Sites: N/A

Brief Summary

This Phase I, randomized, double-blinded, within-subject controlled, two-way crossover study comparing the time to inject (flow rate), safety, and tolerability of a subcutaneously (SC) administered, viscous antibody solution of with and without human recombinant hyaluronidase (rHuPH20) in volunteer subjects. The study hypothesizes that the time required to complete a 20-mL SC injection of a viscous antibody with rHuPH20 will be comparable or shorter than the time required for the injection without rHuPH20.

Conditions

Healthy

Keywords

hyaluronidase; subcutaneous drug delivery; Volunteer Subjects

Outcome Measures

Primary Outcomes (1)

• The time to inject 20 mL of a viscous antibody solution with and without rHuPH20.

Secondary Outcomes (1)

• Assess the time required for a subcutaneous injection with various doses of rHuPH20, safety, tolerability.

Interventions

Hylenex DRUG

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteers of either sex, age 18 to 65 years, inclusive.
• Intact normal skin on both upper extremities without tattoos or potentially obscuring pigmentation or lesions.
• Vital signs (BP, HR, temperature, respiratory rate) within normal range.
• Metabolic panel (e.g., sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, AST, ALT, alkaline phosphatase, total bilirubin, albumin, and total protein) within normal range within 7 days of injection.
• A negative serum or urine pregnancy test (if female of child-bearing potential) within 7 days of injection.
• Female subjects of child-bearing potential must be practicing effective birth control or abstinence currently and plan to continue to do so for the duration of the study.
• Decision-making capacity and willingness and ability to comply with the requirements for full completion of the trial.
• Willingness and ability to sign an informed consent document.

You may not qualify if:

• Upper extremity edema.
• Upper extremity pathology that could interfere with any protocol-specified outcome assessment (e.g., cellulitis, lymphatic disorder or prior surgery, preexisting pain syndrome, previous mastectomy and/or axillary lymph node dissection, etc.).
• Contraindication to an antibody, such as known history of anaphylactic or severe systemic reactions.
• Known predisposition to renal insufficiency or renal failure, including diabetes mellitus, volume depletion, sepsis, paraproteinemia, and subjects receiving known nephrotoxic drugs.
• Known allergy to hyaluronidase or any other ingredient in the formulation of Hylenex.
• Known allergy to bee or vespid venom.
• Known coagulopathy.
• Pregnancy or breast-feeding woman.
• Known clinically significant cardiovascular, gastrointestinal, hepatic, neurological, psychiatric, endocrine, cancer, HIV infection, diabetes mellitus, intercurrent illness such as influenza, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results.
• Participation in a study of any investigational drug or device within 30 days of enrollment in this study.

Sponsors & Collaborators

• Halozyme Therapeutics: lead

Study Officials

• Anoshie Ratnayake, M.D.

  Principal Investigator

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: February 14, 2007
• First Posted: February 15, 2007
• Study Start: February 1, 2007
• Study Completion: May 1, 2007
• Last Updated: October 17, 2011

Record last verified: 2007-02